Lets look at how we got here: BPC-157 is not new
D.RimessiA.AnelliT.PintonP.SitiaR
Hypoxia responsive nano-drug delivery system based on angelica polysaccharide for liver cancer therapy
5 DPP-IV inhibitory activity DPP-IV is a plasma membrane glycoprotein that cleaves N-terminal dipeptides from incretin hormones, such as glucose-dependent insulinotropic peptide (GIP) and glucagon peptide-1 (GLP-1), which are critical for glucose regulation [154]
This article highlights how ongoing studies and the search for effective therapies supported by technology conducts research to improve the lives of those affected, as noted by other researchers, leading to significant discovery, new knowledge, development, accepted theories, experimentation, published studies, articles, and publication of a cure through studious inquiry
Haddick PC, Larson JL, Rathore N, Bhangale TR, Phung QT, Srinivasan K, et al